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BERRY PREPARATIONS AND EXTRACTS 
This application claims the bene?t of priority of US. Pro 
visional Patent Application Ser. No. 60/720,892 ?led on Sep. 
27, 2005, the disclosure of Which is incorporated in its 
entirety herein by reference. 
TECHNICAL FIELD 
The present invention relates to compositions having anti 
oxidant and anti-in?ammatory activity, derived from a berry. 
In particular, the invention relates to a method for deriving an 
extract having antioxidant and anti-in?ammatory activity 
from a berry, and to formulated compositions derived by the 
method for oral and topical administration. Still further, the 
invention provides methods and compositions for treatment 
of in?ammation, oxidative stress, or cancer comprising 
administering an effective amount of the composition of the 
invention. 
BACKGROUND OF THE INVENTION 
Polyphenolics (also knoWn as phenolics) are metabolites 
found in plants, fruits, and vegetables. Phenolics have a num 
ber of functions including acting as free radical scavengers. 
Thus, phenolics disrupt many biological processes. The most 
notable type of phenolics are ?avonoids Which consist of 
proanthocyanidins, anthocyanidins, ?avones, ?avonols and 
their glycosides (Macheix, 1990). Anthocyanins are respon 
sible for the red, purple, and blue colors of many fruits and 
vegetables. The term anthocyanin refers to a group of pig 
ments found in plants, fruits, and vegetables that can be 
classi?ed as both ?avonoid and phenolic. Anthocyanins are 
not found in animals, microorganisms, or marine plants. It is 
thought that anthocyanins function by attracting insects to 
promote pollination but also to protect the plants from dam 
age caused by ultraviolet (UV) radiation. Anthocyanins are 
glycosides of polyhydroxyl and polymethoxyl derivatives of 
2-phenylbenZopyrylium or ?avylium salts, and are soluble in 
Water. The anthocyanins are electron de?cient, and are there 
fore are strong scavengers for reactive oxygen species (ROS) 
such as free radicals. Although there are hundreds of different 
anthocyanins found in nature, six anthocyanin compounds 
predominate including: delphinidin, petunidin, cyanidin, pel 
argonidin, peonidin, and malvidin. The daily intake of antho 
cyanins in the United States is about 180-215 mg/day, and 
constitute the largest intake of phenolic compounds (Hertog, 
1 993). 
Anthocyanins originally dreW interest due to their role in 
color degradation in fruits, and their potential use as natural 
food colorants. More recently, anthocyanins have received 
attention because of their possible health bene?ts as natural 
antioxidant and anti-in?ammatory compounds, and poten 
tially as anti-cancer compounds. Antioxidant property, 
effects, or activity refers to compositions that inhibit, reduce, 
or reverse oxidation or the effects of oxidation, such as for 
example the oxidative process caused by free radicals. A free 
radical may be any chemical species that includes one or more 
unpaired electrons, and Without limitations includes chemi 
cals such as hydroxyl radical, superoxide radical, nitric oxide, 
and nitrogen dioxide. Examples of conditions involving free 
radical oxidative damage include, but are not limited to, 
aging, disease, stress, ultraviolet radiation, exercise, cancer, 
smoking, atherosclerosis, and chronic in?ammation. Studies 
shoWed that antioxidant activity of cyanidins Was greater than 
that of vitamin E and Trolox, and comparable to that of 
butylated hydroxytoluene (BHT) and butylated hydroxyani 
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sole (BHA) (Wang et al., 1997; Rice-Evans et al., 1995; Liu et 
al., 2002; Proteggente et al., 2002; Wang et al., 1999). 
In?ammation, or the biological state of being in?amed, is 
generally characterized by pain, redness, and sWelling, and 
may result from physical causes such as injury, chemical 
causes such as exogenous substances including toxins, or 
biological causes such as infection by a virus, a bacteria, a 
parasite, or other disease-causing agent. As examples, various 
conditions associated With in?ammation of the gastrointesti 
nal tract are knoWn, including but not limited to acute or 
chronic conditions or diseases such as in?ammatory boWel 
disease, gastroesophageal re?ux disease, diarrhea, radiation 
induced enteritis, chemotherapy-induced enteritis, Crohn’s 
disease, irritable boWel syndrome, diverticulitis, ulcers, coli 
tis, viral infection, bacterial infection, and parasitic infection 
or infestation. In individuals a?llicted With the above and 
similar conditions, affected cells such as dendritic cells, 
monocytes, macrophages, ?broblasts, endothelial cells, and T 
cells release causative agents, including cytokines such as 
interleukins (IL), tumor necrosis factor (TNF), interferons 
(IFN), and the like Which trigger in?ammation and/or an 
in?ammatory response. Cytokines important in in?ammation 
include, but are not limited to, IL-1, IL-6, IL-12, TNF-ot, and 
IFN-ot. Anti-in?ammatory properties, effects, or activity 
refers to reducing in?ammation and promoting healing of 
cells and tissues subject to in?ammation and/or in?ammatory 
processes. 
Anti-cancer property, effect, or activity refers to a property 
of a substance, chemical, or material that can sloW the prolif 
eration of tumor cells (termed anti-proliferative effect), or kill 
tumor cells (termed cytotoxic effect). Recent studies have 
shoWn also that berries such as black raspberries possess 
cancer-preventing properties at both in-vitro and in-vivo lev 
els (Kresty et al., 2001; Castro et al., 2002; Xue et al., 2001; 
Huang et al., 2002; Rodrigo et al, in press; US. patent appli 
cation Ser. No. 10/951,413). In particular, anthocyanins have 
been shoWn to demonstrate a Wealth of chemopreventive 
properties (Hecht et al., in press; Liu et al., 2002; Katsube et 
al., 2003; Hu et al., 2003). 
HoWever, anthocyanin compounds are inherently unstable 
both in vivo and in vitro, and tend to degrade over time, 
negating any health or medical bene?ts associated thereWith 
(Rubinskiene et al., 2005; Nielsen et al., 2003; Morais et al., 
2002). A need in the art therefore exists for methods for 
preparing compositions from anthocyanin-containing fruits 
such as berries Which provide a stable anthocyanin content. 
Still further, there is a need for compositions including such 
stable anthocyanin compositions to provide health and medi 
cal bene?ts to individuals utiliZing them. In particular, com 
positions formulated for oral administration and topical 
administration are described herein. HoWever, it Will be 
appreciated that other formulations are contemplated and can 
be derived by the skilled artisan from the teachings herein 
using methods knoWn in the art, including injectable formu 
lations. Accordingly, the present invention contemplates also 
injectable formulations including, but not limited to, solu 
tions, suspensions, emulsion, microemulsions, micelles, lipo 
somes, nanoparticles, microparticles, implants, depots, and 
polymer conjugates. 
SUMMARY OF THE INVENTION 
The present invention provides methods for deriving stable 
compositions from blackberries, and compositions incorpo 
rating such stable compositions. In one aspect, a method is 
provided for preparing a composition having antioxidant and 
anti-in?ammatory activity, comprising exposing a berry to a 
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solvent composition having a pH of from about 1 to about 3, 
and recovering a berry extract having a stable anthocyanin 
content. The berry may be a blackberry. In one embodiment, 
the method comprises the steps of physically disrupting a 
quantity of berries, exposing the physically disrupted berries 
to the solvent composition, and recovering a berry extract 
having a pH of from about 1.0 to about 4.5. The berry extract 
so recovered typically comprises at least one stable anthocya 
nin in an amount effective to provide antioxidant and anti 
in?ammatory activity. In another embodiment, the recovered 
berry extract has a pH of from about 2 to about 3.5. The 
physically disrupted berries may be deWatered prior to being 
exposed to the solvent composition, afterbeing exposed to the 
solvent composition, or both. 
In another aspect, the present invention provides stabiliZed 
compositions having antioxidant and anti-in?ammatory 
activity, prepared by the method of the invention as described 
above. In one embodiment, a composition is provided having 
antioxidant and anti-in?ammatory activity, comprising a 
berry extract having at least one stable anthocyanin in an 
amount effective to provide antioxidant and anti-in?amma 
tory activity. The berry extract is provided by the steps of 
physically disrupting a quantity of berries and exposing the 
physically disrupted berries to a solvent composition having 
a pH of from about 1 to about 3, Which stabiliZes the at least 
one anthocyanin. The berry extract may be derived from a 
blackberry. Compositions comprising the berry extract of the 
present invention, formulated for oral and/ or topical admin 
istration, are provided also, including Without gels, vanishing 
lotions, vanishing creams, and the like. 
In yet another aspect, the present invention provides meth 
ods for treatment of in?ammation, oxidative stress, or cancer 
in a mammal in need thereof, comprising administering an 
effective amount of the composition of the invention. Still yet 
further, another aspect of the invention is compositions com 
prising a therapeutically effective amount of the composition 
of the invention, formulated in a pharmaceutically acceptable 
vehicle. The composition may be provided in combination 
With additional anticancer agents, additional anti-oxidant 
agents, and/ or additional anti-in?ammatory agents. 
As should be appreciated, the embodiments shoWn and 
described herein are an illustration of one of the modes best 
suited to carry out the invention. It Will be realiZed that the 
invention is capable of other different embodiments and its 
several details are capable of modi?cation in various, obvious 
aspects all Without departing from the invention. Accord 
ingly, the draWings and descriptions Will be regarded as illus 
trative in nature, and not as restrictive. Unless otherWise 
indicated, all patents, patent applications, and non-patent 
documents referenced in the present disclosure are incorpo 
rated herein by reference in their entirety. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying draWings incorporated in and forming 
a part of the speci?cation, illustrate several aspects of the 
present invention and together With the description serve to 
explain the principles of the invention. In the draWings: 
FIG. 1 shoWs percent Weight increase of active blackberry 
poWder as a function of time When stored at 25° C. and at 40 
C.; 
FIG. 2 depicts a standard HPLC chromatogram of a black 
berry extract made according to the present invention; 
FIGS. 3A and 3B shoW the stability of anthocyanins as a 
function of pH and time; 
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FIG. 4 shoWs the stability of a speci?c anthocyanin (cya 
nidin-3-glucoside) in a blackberry preparation made accord 
ing to the present invention as a function of time and storage 
condition; 
FIGS. 5A and 5B shoW the stability of anthocyanins in 
blackberry preparations made according to the present inven 
tion as a function of time and temperature; 
FIG. 6 presents a dissolution pro?le of enteric-coated hard 
capsules containing a berry composition according to the 
present invention; 
FIG. 7 shoWs a dissolution pro?le of enteric-coated hard 
capsules containing a berry extract according to the present 
invention; 
FIG. 8 shoWs inhibition of proliferation of HT-29 cells by 
a blackberry extract according to 
FIG. 9 shoWs inhibition of IL-12 release from murine den 
dritic cells by a blackberry extract according to the present 
invention. 
Reference Will noW be made in detail to the present pre 
ferred embodiment of the invention, an example of Which is 
illustrated in the accompanying draWings. 
DETAILED DESCRIPTION OF THE INVENTION 
Blackberries and raspberries, sometimes referred to as 
“brambles”, are a species of fruit in the genus Rubus. Rubus is 
quite diverse and has 12 subgenera With several of the sub 
genera having more than a hundred species. In the United 
States, R. allegheniensis, R. argulus, R. cuneifolius, R. 
Canadensis, and R. Zrivialis are the dominant Rubus species. 
Blackberries belong to the subgenus Eubatus, and have much 
greater complexity than raspberries in terms of genetic back 
ground, groWth characteristics, and number of species. 
Blackberries are native to Asia, Europe, North and South 
America. They have been groWn in Europe for over 2000 
years as food and for medical applications. Blackberries groW 
in three different forms: trailing, semi-erect, and erect. In the 
eastern half of the United States, the dominate form is the 
erect including the thorny types, Cherokee, Comanche, Chey 
enne, DarroW, Illini Hardy Blackberry, ShaWnee, and Choc 
taW. The thornless cultivars include Hull, Chester, Navaho, 
and Arapaho. Other types of blackberries include, but are not 
limited to, Eldorado, Ebony King, Raven, Ranger, Hedrick, 
Bailey, and BraZos. Semi-erect blackberries requiring a trellis 
for production include Black Satin, Chester, Dirksen, Hull 
Thornless, Smoothstem, and Thomfree. In the Paci?c North 
West, blackberries are often called Marionberries. Other ber 
ries that have genetic similarity to blackberries include Boy 
senberry, Loganberry, Olallieberry, and Youngberry. A 2002 
report by the USDA lists the total US production of all black 
berry types to be about 56 million pounds groWn on 8370 
acres. According to the USDA, of the blackberries harvested 
in the US, about 40% are used for jams and jellies, 25% for 
bakery products, 23% froZen or canned, and the 12% for 
juices or other food. 
Tsao et al. (2003) shoWed that, relative to other fruits, 
blackberries have high concentrations of polyphenolics such 
as anthocyanins With as much as 1923 ug/ g Wet fruit. Sellap 
pan et al. (2002) shoWed that blackberries had high concen 
trations of ellagic acid; ChocktaW had 33.81 mg/100 g berry 
and KioWa had 30.01 mg/100 g berry. Blackberries Were also 
found to contain ?avonoids, With the major ?avonoid, cat 
echin, present in ChoctaW at 312.86 mg/ 100 g berry. Sellap 
pan shoWed that the average total anthocyanin and polyphe 
nolic content in blackberries Was 116.591858 mg/100 g 
berry and 486.53:97.13 mg/100 g berry, respectively. 
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Accordingly, in one embodiment the present invention 
describes methods for deriving stable compositions from 
blackberries, and compositions made by those methods. 
However, it Will easily be to many other types of fruits, plants, 
and vegetables having an anthocyanin content, including but 
not limited to: straWberries, black raspberries, apple, cra 
bapple, chokeberry, HaWthorn, Juneberry, Loquat, pear, apri 
cot, cherry, plum, peach, various other raspberries, cloud 
berry, Wineberry, salmonberry, bearberry, bilberry, cranberry, 
huckleberry, barberry, currant, elderberry, gooseberry, hack 
berry, honeysuckle, nannyberry, sheepberry, sea grape, Wolf 
berry, croWberry, goumi, kiWi, various other grapes, thimble 
berry, salmonberry, various types of melons such as 
Watermelon, ?g, lime, avocado, feijoa, guava, kumquat, lon 
gan, lychee, passion fruit, and pineapple. 
In one aspect, the present invention provides a method for 
preparing a composition having antioxidant and anti-in?am 
matory activity, comprising exposing a berry to a solvent 
composition having a pH of from about 1 to about 3, and 
recovering a berry extract having a stabiliZed anthocyanin 
content. As discussed above, the berry may be a blackberry. In 
one embodiment, the method comprises the steps of: physi 
cally disrupting a quantity of berries, exposing the physically 
disrupted berries to the solvent composition, and recovering a 
berry extract having a pH of from about 1.0 to about 4.5. It 
Will be appreciated that the ?nal pH of the extract Will depend 
on both the concentration of the berry extract in the solvent 
composition and on the speci?c solvent composition used for 
extraction. The berry extract so recovered typically comprises 
at least one stabiliZed anthocyanin in an amount effective to 
provide antioxidant and anti-in?ammatory activity. In 
another embodiment, the recovered berry extract has a pH of 
about 3 .5. The stabiliZed anthocyanin may be a delphinidin, a 
petunidin, a cyanidin, a pelargonidin, a peonidin, a malvidin, 
or any combination thereof. 
The physically disrupted berries may be exposed to a sol 
vent composition comprising an alcohol and at least one acid, 
With the acid provided in a suf?cient amount Whereby the 
solvent composition has a pH of from about 1 to about 3. The 
acid may be provided in an amount of from about 0.005% to 
about 3% (v/v) of the alcohol. In one embodiment, the acid is 
provided in an amount of from about 0.01% to about 2% of 
the alcohol (v/v). In yet another embodiment, the acid is 
provided from about 0.01% to about 1% of the alcohol (v/v). 
Any of a number of alcohols may be suitable for the present 
invention, including, but not limited to, loWer chain alcohols 
such as methanol, ethanol, propanol, butanol, and mixtures 
thereof. The acid may be any acid suitable for providing the 
desired pH for the solvent composition, including, but not 
limited, to hydrochloric acid, acetic acid, citric acid, lactic 
acid, tri?uoroacetic acid, aspartic acid, glutamic acid, sulfur 
containing acids such as sulfonic acid, phosphoric acid, 
maleic acid, and mixtures thereof. In yet another embodi 
ment, the alcohol can be replaced With a suitable ketone or a 
suitable halogenated ole?n, such as acetone, chloroform, 
methylene chloride, or mixtures thereof. 
The physically disrupted berries may be deWatered to a 
residual Water content of up to 20% composition, or both. In 
one embodiment, the physically disrupted berries are deWa 
tered to a residual Water content of up to 10% (W/v). It Will be 
appreciated that any suitable method may be employed for 
deWatering, such as heating or centrifuging a berry puree to 
remove Water, folloWed by crushing the dried berry puree to a 
poWder. Typically, a poWder in accordance With the present 
invention is prepared by lyophiliZation or freeZe-drying, i.e., 
freeZing folloWed by removal of Water by sublimation. Ben 
e?cially, freeZe-drying provides a chemically and physically 
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stable, free -?oWing dry poWder. Optionally, a cryoprotectant 
may be added to material being freeZe-dried to reduce or 
prevent chemical or physical damage to the material. Suitable 
cryoprotectants include, but are not limited to, monosaccha 
rides such as glucose, fructose, maltose, ribose, mannose, and 
xylose, disaccharides such as trehalose, sucrose, myoinositol, 
phosphorylated inositols, and glycerol, polysaccharides such 
as hydroxyethyl starch, dextran, and hyaluronic acid, and 
polymers such as polyvinylpyrrolidone and chitosan. 
In another aspect, the present invention provides composi 
tions having antioxidant and anti -in?ammatory activity, pre 
pared by the method of the invention as described above. In 
one embodiment, a composition is provided having antioxi 
dant and anti-in?ammatory activity, comprising a berry 
extract having at least one stabiliZed anthocyanin in an 
amount effective to provide antioxidant and anti-in?amma 
tory activity. The berry extract may be provided by the steps 
of physically disrupting a quantity of berries and exposing the 
physically disrupted berries to a solvent composition Which 
stabiliZes the at least one anthocyanin. The berry extract may 
be derived from a blackberry. In one embodiment, the berry 
extract has a pH of from about 1.0 to about 4.5. In another 
embodiment, the berry extract has a pH of about 3.5. The 
stabiliZed anthocyanin may be a delphinidin, a petunidin, a 
cyanidin, a pelargonidin, a peonidin, a malvidin, and combi 
nations thereof. 
The solvent composition may comprise an alcohol and at 
least one acid, Wherein the acid is provided in an amount 
suf?cient Wherein a pH of the solvent composition is from 
about 1 to about 3. The acid may be provided in an amount of 
from about 0.005% to about 3% (v/v) of the alcohol. The 
alcohol may be any suitable alcohol, including but not limited 
to loWer chain alcohols such as methanol, ethanol, propanol, 
butanol, and mixtures thereof. The acid may be any acid 
suitable for providing the desired pH of the solvent compo 
sition, including, but not limited to, hydrochloric acid, acetic 
acid, citric acid, lactic acid, tri?uoroacetic acid, aspartic acid, 
glutamic acid, formic acid, phosphoric acid, maleic acid, and 
combinations thereof. Optionally, in place of the alcohol a 
suitable ketone or a suitable halogenated ole?n may be used, 
such as acetone, chloroform, methylene chloride, and mix 
tures thereof. As discussed above, the physically disrupted 
berries may be deWatered to a Water content of up to 20% 
(W/v), such as by freeZe-drying, either prior to exposing to the 
solvent composition, after exposing to the solvent composi 
tion, or both. Still further, a cryoprotectant may be 
A variety of formulations for oral and/ or topical adminis 
tration are contemplated for the composition of the present 
invention. In one embodiment, a formulation for oral admin 
istration is provided, comprising the berry extract in an 
amount of from about 3% (W/W) to about 90% (W/W). In 
another embodiment, a formulation for topical administration 
is provided, comprising the berry extract in an amount of from 
about 1% (W/W) to about 20% (W/W). It Will be appreciated by 
the skilled artisan that a large number of topical and oral 
formulations are knoWn in the art, such as nutritional supple 
ments, capsules, enteric-coated capsules, ?lm-coated cap 
sules, tablets, enteric-coated tablets, ?lm-coated tablets, 
cheWing gums, lotions, creams, mucoadhesive gels, vanish 
ing lotions, vanishing creams, and the like. Other Ways to 
apply a composition topically formulations are knoWn, 
including but not limited to: sprays, ointments, gels, patches, 
and needle-free devices that deliver their contents by diffu 
sion, mechanical or gas-driven energy. The making of such 
formulations and/or devices is Well Within the ability of the 
skilled artisan, and such formulations and methods are con 
templated also by the present invention. 
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For example, it is known to provide compositions in emul 
sion or microemulsion form, as lotions and/or creams. A 
lotion refers to a semi-viscous emulsion that is meant to be 
applied to the skin. A cream refers to a more viscous emulsion 
that is also meant to be applied to the skin. Lotions and creams 
may be of the oil-in-Water or Water-in-oil type. In one 
embodiment of the present invention, lotions and creams of 
the oil-in-Water type are provided Which stabilize a compo 
sition according to the present invention, and/or promote its 
penetration into or through the skin layers. 
An emulsion refers to a biphasic opaque mixture of tWo 
immiscible liquids stabiliZed by a surfactant. Emulsions are 
thermodynamically unstable systems, and usually require the 
application of high-torque mechanical mixing or homogeni 
Zation to produce dispersed droplets in the range of about 0.2 
to 25 um. In contrast, a microemulsion is a stable biphasic 
mixture of tWo immiscible liquids stabiliZed by a surfactant 
and usually a co-surfactant. Microemulsions are thermody 
namically stable, isotropically clear, form spontaneously 
Without excessive mixing, and have dispersed droplets in the 
range of about 5 nm to 140 nm. Both microemulsions and 
emulsions can be made as Water-in-oil or oil-in-Water sys 
tems. In a Water-in-oil system, the dispersed phase is Water 
and the continuous phase is oil. In an oil-in-Water system, the 
dispersed phase is oil and the continuous phase is Water. 
Whether Water-in-oil or oil-in-Water systems Will form is 
largely in?uenced by the properties of the surfactant. The use 
of surfactants that have hydrophilic-lipophilic balances 
(HLB) of about 3-6 tend to promote the formation of Water 
in-oil microemulsions While those With HLB values of about 
8-18 tend to promote the formation of oil-in-Water micro 
emulsions. 
Formulations contemplated for oral administration 
directly to the gastrointestinal tract include, but are not lim 
ited to, nutritional supplements, capsules, enteric-coated cap 
sules, ?lm-coated suspensions. It is envisioned that more 
novel particle-based suspensions for oral administration can 
be produced, such as emulsions, microemulsions, nanopar 
ticle or microparticle suspensions. It is also contemplated in 
this invention that a formulation for oral administration may 
be prepared that is delivered to and retained in the mouth, 
Whereby the contents and/ or the active ingredient primarily 
drain into the stomach. Formulations meeting these criteria 
include, but are not limited to, cheWing gums, gels, sprays, 
loZenges, lollipops or other candies, rapidly dissolving strips, 
and the like. In one embodiment, the formulation for oral 
administration is a tablet or hard-gelatin capsule. In another 
embodiment, the formulation is coated With a substance to 
control the rate or location of disintegration, i.e., an enteric 
coated or ?lm-coated formulation. 
The present invention contemplates providing enteric 
coated oral formulations. An enteric-coating refers to a coat 
ing on an oral dosage form that is meant to cause the oral 
dosage form to remain intact in the loWer pH of the stomach, 
but disintegrate once the dosage form reaches the higher pH 
of the intestines including the small intestines, large intes 
tines, colon, or rectum. The most common enteric coatings 
are those that remain intact (undissociated) in the loW pH of 
the stomach, but ioniZe When the pH is above pH 4-5, pH 5-7, 
or even above pH 7. Common enteric-coating materials 
include, but are not limited to, cellulose acetate phthalate, 
polyvinyl acetate phthalate, hydroxypropylmethyl cellulose 
phthalate, cellulose acetate trimellitate, carboxymethyl eth 
ylcellulose, and hydroxypropyl methylcellulose acetate suc 
cinate, and polymethacrylates (methacrylic acid copolymer) 
including EUDRAGIT-based polymers. It is also contem 
plated to provide ?lm-coated oral formulations. A ?lm-coat 
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ing typically targets the coated substance to the colon by 
remaining undissociated or stable until a pH 7 environment is 
reached. Film -coating materials to achieve this goal include, 
but are not limited to, EUDRAGIT-based polymers that are 
soluble in intestinal ?uid at a pH greater than 7, pectin, amy 
lose, and chitosan-based polymers. 
It is also envisioned that a colon or tumor-speci?c ?lm 
coating can be used on the oral dosage form that effectively 
serves to increase the delivered concentration of the compo 
sition of the present invention by selective removal of the 
coating by an endogenous enZyme present in the target tissue 
of the small intestines, large intestines, colon, or rectum. 
Alternatively, it is envisioned that tumors in the colon or 
rectum can be targeted by coating the dosage form With a 
ligand speci?c for the tumor cell surface, i.e., Without limita 
tion an antibody or binding fragment thereof. 
A cheWing gum is a ?avored composition that is meant to 
deliver a ?avor or other substance by cheWing. The primary 
part of cheWing gum is the gum base, Which is a non-nutritive 
substance. The gum base may consist of any one or more of 
the folloWing; an elastic ingredient, a resin that acts as a 
binder and softener, a plasticiZer, ?llers, a sWeetener or ?a 
voring agent, and an antioxidant. As an example, Subpart G 
titled “Gum, CheWing Gum Bases and Related Substances” 
may be used in gums, including arabinogalactan, natural gum 
bases including chicle, chiquibul, croWn gum, gutta hang 
kang, massaranduba balata, massaranduba chocolate, nis 
pero, rosidinha, Venezuelan chicle, jelutong, leche capsi 
(solva) perillo, leche de vaca, niger gutta, tunu, chilte, natural 
rubber (smoked sheet and latex solids), synthetic substances 
such as butadiene-styrene rubber, isobutylene-isoprene 
copolymer, para?in, petroleum Wax, petroleum Wax syn 
thetic, polyethylene, polyisobutylene, and polyvinyl acetate, 
plasticiZing materials including glycerol ester of partially 
dimeriZed rosin, glycerol ester of partially hydrogenated gum 
or Wood rosin, glycerol ester of polymeriZed rosin, glycerol 
ester of gum rosin, glycerol ester of tall oil rosin, glycerol 
ester of Wood rosin, lanolin, methyl ester of rosin partially 
hydrogenated, pentaerythritol ester of partially hydrogenated 
gum or Wood rosin, rice bran Wax, stearic acid, sodium and 
potassium stearates, synthetic and natural terpene resins, anti 
oxidants including butylated hydroxyanisole, butylated 
hydroxytoluene, propyl gallate, carrageenan, carrageenan 
With polysorbate 80, salts of carrageenan, furcelleran, salts of 
furcelleran, gellan gum, and xanthan gum. Of course, com 
positions in addition to those of the present invention may be 
included as is knoWn in the art to provide desirable attributes 
for the gum, such as enjoyment (taste, mouth-feel, and the 
like), breath freshening, dental care, and oral care. 
Still further, the compositions of the present invention may 
be provided along With a mucoadhesive polymer excipient, 
for direct delivery to a mucosal surface and also for transmu 
cosal delivery into systemic circulation. Brie?y, mucoadhe 
sive polymer excipient refers to a polymer that has the ability 
to adhere to mucin. Typically, for the compositions of the 
present invention a mucoadhesive acidic polymer excipient is 
used, Which When dissolved or suspended in Water results in 
an acidic pH. In one embodiment, the mucoadhesive polymer 
Will provide a polymer solution or suspension having a pH of 
from about 1 to about 4.5. The polymer may be non-ionic or 
anionic. Mucoadhesive polymer excipients Will typically be 
selected Which also control the rate of release of the active 
ingredient from the gel by providing a controlled rate of 
polymer rehydration. The mucoadhesive polymer excipient 
may be present in the dosage form in one embodiment in a 
Weight percentage betWeen 5-50%. In another embodiment, 
the excipient is present in a Weight percentage betWeen 
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5-20%. In yet another embodiment, the excipient is present in 
a Weight percentage betWeen 5-10%. As non-limiting 
examples, the mucoadhesive polymer excipient may be 
selected from one or more of the following polymers: poly 
acrylic acid, crosslinked polyacrylic acid, polyvinyl pyrroli 
done, cross-linked polyvinyl pyrrolidone, polymethacrylic 
acid, polymethacrylic -acid co-polymers, carboxymethyl cel 
lulose, cellulose or derivatives thereof, or alginate. 
Of course, additional substances may be included in the 
formulations of the present invention to provide additional 
desired properties, such as sWeeteners or preservatives. 
SWeeteners glycerol, lactitol, maltitol, maltose, sorbitol, xyli 
tol, saccharin, aspartame, cyclamate, sucralose, or acesu 
?ame potassium, or mixtures thereof. Preservatives are natu 
ral or synthetic chemicals that are added to hinder spoilage, 
Whether caused by microbial groWth, or unWanted chemical 
changes such as, but not limited to, hydrolysis or oxidation. 
Suitable preservatives may include, but are not limited to, 
benZoic acid, sorbic acid, benZyl alcohol, benZethonium 
chloride, butyl paraben, cetrimide, chlorobutanol, cresol, 
ethyl paraben, phenol, phenoxyethanol, propylene glycol, 
sodium benZoate, thimersol, methyl paraben, propyl paraben, 
or mixtures thereof. 
Still yet further, the present invention provides a method of 
treating in?ammation, oxidative damage, or cancer, compris 
ing administering to a mammal such as a human in need 
thereof an effective amount of a composition as described 
above. The in?ammation may be associated With cancer, 
in?ammatory boWel disease, gastroesophageal re?ux dis 
ease, diarrhea, radiation-induced enteritis, chemotherapy-in 
duced enteritis, Crohn’s disease, irritable boWel syndrome, 
diverticulitis, ulcer, colitis, viral infection, bacterial infection, 
parasitic infection, and combinations thereof. The in?amma 
tion may be partially mediated by the release in the body of 
the mammal of at least one cytokine including, but not limited 
to, an interleukin such as IL- 1, IL-6, or IL-12, or TNF-ot, and 
lFN-ot. The oxidative damage may be mediated at least par 
tially by release of a free radical in the body of the mammal. 
The cancer may be a skin cancer, an oral cancer, a cancer of 
the eye, a cancer of a mucosal surface such as the vagina, the 
nose, and the rectum, and combinations thereof. As described 
above, the composition may be formulated for administration 
by at least one of orally, topically, and by injection. 
In yet still another aspect, the present invention provides 
compositions for treating in?ammation, oxidative damage, or 
cancer in a mammal in need thereof, comprising a therapeu 
tically effective amount of a composition as described above 
in a pharmaceutically acceptable vehicle. The composition 
may further comprise at least one additional anti-cancer 
agent, at least one additional anti-oxidant, at least one addi 
tional anti-in?ammatory agent, and combinations thereof. 
The compositions may be formulated for administration by at 
least one of orally, topically, and by injection as described 
above. 
The examples provided herein are presented in support of 
and to further illustrate the invention as described above and 
in the accompanying draWings, but are not to be considered as 
limited thereto. Citations of literature herein are incorporated 
into this disclosure by reference in their entirety unless oth 
erWise indicated. Generally, 2,2'-AZinobis(3-ethylbenZothia 
Zoline-6-sulfonic acid) diammonium salt (ABTS), Trolox 
(6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid), 
potassium persulfate, formic acid (ACS, >96%), 3-(4,5-dim 
ethyl-thiaZol-2-yl)-2,5-diphenyl tetraZolium bromide 
(MTT), Folin and Ciocalteau phenol reagent and gallic acid 
(98% purchased from Flulca (St. Gallen, SWitZerland). USP 
grade Ethanol (Absolutei200 proof) Was purchased from 
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AAPERAlcohol and Chemical Co. (Shelbyville, Ky.). HPLC 
grade acetonitrile Was purchased from Fisher Scienti?c (Fair 
LaWn, N.J.). 
EXAMPLE 1 
A blackberry puree Was prepared by pulping Whole black 
berries. For purposes of this disclosure, the term pulping 
refers to the process of removing the seeds and skin from 
Whole fruit. HoWever, it Will be understood by those skilled in 
the art that the skin and seeds also contain many biologically 
useful substances and so it is envisioned that the skin and 
seeds may be retained for later use, or alternatively may be 
kept With the fruit pulp rather than separated. 
Blackberries Were picked from the vine and placed in con 
tainers for transporting to the picking station for inspection. 
The berries Were not Washed in order to prevent deterioration 
of the Whole berry by surface Water. The seeds and skin of the 
berries Were removed using a Langsenkamp type 161 Colos 
sal Pulper having tWo agitator arms With brushes With a 
stainless steel chamber, and stainless steel catch pan With tWo 
outlets (one threaded and one With a sanitary ?tting) With a 
10-horse poWer, 3 phase, 60 cycle, 230/460 volt meter. Whole 
blackberries Were passed through the Lagsenkamp Pulper at 
a rate of 50-75 gallons/minute to produce a homogenous 
blackberry puree free of skin and seeds. The blackberry puree 
Was stored froZen at —200 C. 
EXAMPLE 2 
A VirTis Model AD2 LyophiliZer Was used to freeze-dry a 
blackberry puree, prepared as described in Example 1, to 
produce a free-?oWing poWder. The cycle used a freeZer 
temperature of —400 C., a condenser temperature of —500 C., 
and vacuum of 200 mTorr. Approximately 10 g of blackberry 
puree in a glass lyophiliZation vial Was freeZe-dried. The 
folloWing drying steps Were used to prepare a purple cake of 
freeZe-dried blackberry puree: 
TABLE 1 
Example Freeze-Drying Cycle for Blackberry Puree to 
Produce Active Pharmaceutical Powder 
Temp Vacuum 
Drying Steps (0 C.) Time (min) (mTorr) 
1 —35 10 200 
2 —30 5 200 
3 —25 5 200 
4 —20 1200 200 
5 — 1 5 840 200 
6 — 1 0 10 200 
7 —5 10 200 
8 0 10 200 
9 5 120 200 
10 10 3 00 200 
1 1 15 10 200 
12 20 180 200 
Post Heating 25 90 200 
The freeZe-dried blackberry puree Was collected from the 
glass lyophiliZation vial and milled using a mortar and pestle 
to produce a free-?oWing reddish-purple poWder. 
EXAMPLE 3 
A Hull lyophiliZer Was employed to create a second 
embodiment of a dry poWder of the blackberry puree. A 
partially froZen blackberry puree (Example 1) (5204 g) Was 
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placed into the lyophilizer on metal pans in large chunks. The 
following lyophilization cycle shown in Table 2 Was used to 
dry the blackberry puree: 
TABLE 2 
Lyophilization Cycle Used to Produce 
Freeze-Dried Blackberry Powder 
Steps 
. Freeze to —40° C. 
. Raise temp to —35° C. 
. Once at —35° C., hold for 3 hr 
. Set vacuum to less 150 microns 
. Raise temp to —10° C. 
. Once at —10° C., hold for 3 hr 
. Maintain vacuum of less than 150 microns 
. Raise temp to 0° C. 
. Once at 0° C., hold for 3 hr 
. Raise temp to 5° C. 
. Once at 5° C., hold for 2.5 hr 
. Raise temp to 10° C. 
. Once at 10° C., hold for 2.4 hr 
. Raise temp to 20° C. 
. Once at 20° C., hold for 2.5 hr 
. Break vacuum 
20 
12 
for 30 min With 60 mL of ethanol containing 0.01% HCl. The 
supematants Were collected after ?ltration and dried by rotary 
evaporation at 40° C. The dried extract Was dissolved in 10 
mL of deionized Water and ?ltered through a 1.0 pm nylon 
syringe ?lter. The blackberry extract had a pH of 1.9. The 
extract Was either frozen at —20° C., or lyophilized to produce 
a dried blackberry extract (DBE) and then stored as a poWder 
at —20° C. The average yield ofDBE Was 470.44:9.27 mg per 
gram of blackberry poWder. 
The blackberry extract Was characterized for: i) mono 
meric anthocyanins and polymeric color measurement, ii) 
Total Phenolic Measurement, iii) Trolox Equivalent Antioxi 
dant Capacity (TEAC) Assay, and iv) anthocyanin composi 
tion. Results of characterization for i, ii, and iii are shoWn in 
Table 3 beloW. It is important to note that the values for these 
several parameters are likely in?uenced by the extraction 
ef?ciency of the berry extract. Thus, it may be appreciated by 
those skilled in the art that a different extraction protocol may 
result in a berry extract that has different composition and 
features. 
TABLE 3 
The resulting blackberry poWder Weighed 559 g and Was 
10.7% W/W of the initial blackberry puree that Was lyo 
philized. Next, 100 g of the freeze-dried blackberry poWder 
Was treated under sonication With 500 mL ethanol containing 
0.01% HCl for 30 min to produce a blackberry extract having 
a pH in the range of 1.9-2.0. The suspension Was ?ltered and 
the supernatant Was collected in a ?ask. The supernatant Was 
dried at 400 C. for 7 hr using a rotary evaporator. The recov 
ered blackberry extract Weighed 19.12 g or 19.12% W/W of 
the original 100 g dried blackberry poWder. 
EXAMPLE 4 
Five hundred milligram portions of blackberry poWder 
prepared as described in Example 2 Were evaluated for rate of 
Water sorption. Three vials Were held at 25° C. and three vials 
Were held at 40 C. The percentage Weight increase over time 
due to Water sorption Was recorded for a period of 45 hr. As 
shoWn in FIG. 1, blackberry poWder stored at 25° C. increased 
in Weight by up to 10% by 30 hr, and then reached a plateau. 
In contrast, blackberry poWder stored at 40 C. increased in 
Weight by less than 1 .7% and reached a plateau after only 5 hr. 
EXAMPLE 5 
TWo different blackberry extracts Were obtained by sub 
jecting 2.5 g blackberry poWder (Example 2) three times With 
either; sample A) 20 mL of ethanol/0.1% HCl or, sample B) 
20 mL of ethanol/0.01% HCl under sonication. The three 
samples for each extraction condition Were red solution. 
Ethanol Was then removed at 400 C. using a rotary evaporator 
to obtain a dark red, viscous liquid. Ten (10) mL of Water Was 
added to sample A to produce a dark-red suspension having a 
pH of 1.2. Ten (10) mL of Water Was added to sample B to 
produce a dark-red suspension having a pH of 1.9. Both 
sampleA and sample B Were centrifuged for 10 min at 12,000 
g and a ?nal dark-red solution referred to berry extracts. As 
Will be discussed in greater detail beloW, the resulting com 
positions are enriched for stabilized anthocyanins. 
EXAMPLE 6 
An aliquot of freeze-dried blackberry poWder (2.5 g) pre 
pared as described in Example 2 Was treated under sonication 
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Composition and Characterization of Dried Blackberg Extract DBE 
Total Total TACC 
Anthocyanins" Phenolicsl7 Polymeric (uM TEd/ g 
(mg/g DBE) (mgg DBE) color (%) DBE) 
Blackberry 6.80 z 0.31 17.32 1 0.74 2.2 11.0 66.98 1 1.27 
extract 
(11 = 3) 
“Total anthocyanins Were expressed as cyanidin-3-glucoside equivalent. 
bTotal phenolics Were expressed as gallic acid equivalent. 
CTAC: total antioxidant capacity measured by Trolox-equivalent antioxidant capacity assay. 
dTE: Trolox equivalent. 
i) Monomeric Anthocyanins and Polymeric Color Mea 
surement. Monomeric anthocyanin Were diluted 1:100 v/v in 
a 25 mM potassium chloride buffer (pH 1.0) and a 0.4 M 
sodium acetate buffer (pH 4.5), then read against a blank at 
510 nm and 700 nm With 1 cm path length disposable 
cuvettes. Total anthocyanin content Was calculated using the 
equations beloW. 
A:(A510-A700) PH l-o-(Asro-Avoo) PH 4-5 Equation (1) 
Where: A is the absorbance of the diluted anthocyanin 
sample; 
C is the anthocyanin concentration (mg/ L); 
MW is the molecular Weight (449.2 for cyanidin-3-glu 
coside); 
DF is the dilution factor; and 
e is the molar absorptivity (26900 for cyanidin-3-gluco 
side). 
Color density and polymeric color Were calculated using 
absorption at 420, 510 and 700 nm With and Without bisul?te 
treatment. The percentage of polymeric color Was determined 
by the ratio of polymerized color to color density. 
ii) Total Phenolic Measurement. Total phenolic content in 
the berry extract Was estimated based on the method of 
Singleton and Rossi (1965) using gallic acid as a standard. 
TWenty (20) pL of diluted samples Was added to 1.58 mL 
distilled Water along With 100 pL of a 2N Forlin-Ciocalteu 
phenol reagent. All solutions Were mixed thoroughly and then 
alloWed to sit at room temperature for 1 min. Three hundred 
(300) pl saturated sodium carbonate solution (200 g/L) Was 
then added to each sample. The absorbance Was measured at 









